.Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA31_Pegcetacoplan.Pegcetacoplan .Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA31_Pegcetacoplan.Pegcetacoplan| name: | Pegcetacoplan |
| ATC code: | S01XA31 | route: | subcutaneous |
| n-compartments | 1 |
Pegcetacoplan is a complement C3 inhibitor, primarily used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It is a pegylated cyclic peptide approved for clinical use, offering targeted therapy by inhibiting the complement cascade at the level of C3, thereby controlling hemolysis related to PNH.
Pharmacokinetic parameters were reported in adults with PNH following subcutaneous administration.
Crass, RL, et al., & Langdon, G (2024). Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria. Drugs in R&D 24(4) 563–573. DOI:10.1007/s40268-024-00500-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39612158